The popularity of Sildenafil initially sparked a period of growth for pharma, but recent developments present a complicated picture for investors. Lower-cost versions are reducing revenue, and ongoing litigation add https://imogenpqeg862587.azzablog.com/41616352/sildenafil-and-big-pharma-a-volatile-investment